HWK-007 for Ovarian Cancer

This trial tests a new treatment called HWK-007 for individuals with certain advanced or metastatic solid tumors. The main focus is on the effectiveness and safety of HWK-007 at different doses. The study targets individuals with cancers such as non-squamous EGFR-WT NSCLC (a type of lung cancer), endometrial carcinoma, and ovarian cancer resistant to platinum-based treatments. Ideal candidates are those who have lived with any of these cancers and have not responded well to standard treatments. As a Phase 1 trial, the research aims to understand how the treatment works in people, offering participants the opportunity to be among the first to receive this new treatment.

The trial information does not specify if you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.

Research has shown that HWK-007 is currently under evaluation for safety and effectiveness in treating various types of cancer. This marks the first human trial of HWK-007, so no prior safety data exists for people. The study is in Phase 1, focusing primarily on safety and determining the correct dosage.

Before human testing, lab and animal studies demonstrated that HWK-007 could significantly reduce tumors. Although these results are promising, they do not guarantee similar effects in humans.

Most treatments for ovarian cancer, like chemotherapy, target rapidly dividing cells. But HWK-007 works differently, as it is a PTK7-directed antibody-drug conjugate (ADC). This means it specifically targets the PTK7 protein, which is often found on cancer cells, delivering the drug directly to the tumor and potentially reducing damage to healthy cells. Researchers are excited about HWK-007 because this targeted approach could lead to more effective treatments with fewer side effects compared to traditional therapies.

Research has shown that HWK-007 targets a protein called PTK7, often found in large amounts in some cancers, such as ovarian cancer. Studies indicate that PTK7 is linked to cancer spreading and treatment resistance. HWK-007 is designed to attach to PTK7 and deliver cancer-fighting drugs directly to the tumor. Early tests in the lab and in animals suggested that HWK-007 could outperform previous treatments for ovarian cancer. Its effectiveness stems from targeting PTK7, present in about 70% of certain tumors. Participants in this trial will receive HWK-007 in different dosing regimens to evaluate its safety and effectiveness.¹³⁶⁷⁸